HQH (HQH) Stock Price & Analysis
HQH (HQH) rose 0.69% to USD 18.9 as of June 10, 2026 at 00:54 UTC, according to Nexqual real-time market data.
HQH last closed at USD 18.77; the session ranged USD 18.64–19.26 on volume of 129,887 shares. Market capitalization is $1.08B, with a 52-week range of USD 15.09–20.46 (NYQ). Source: Nexqual, June 10, 2026 at 00:54 UTC.
Key Statistics (as of June 10, 2026 at 00:54 UTC)
| Price | USD 18.9 |
|---|---|
| Change | ▲ 0.69% (up) |
| Previous Close | USD 18.77 |
| Open | USD 18.97 |
| Day Range | USD 18.64 – 19.26 |
| 52-Week Range | USD 15.09 – 20.46 |
| Volume | 129,887 shares |
| Market Cap | $1.08B |
| Exchange | NYQ |
Technical Analysis (HQH)
Nexqual's technical model rates HQH "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:54 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.61 (neutral) |
| vs SMA50 | Below (USD 19.42) |
| MACD | -0.17 (negative) |
Analyst Ratings (HQH)
Wall Street analysts rate HQH "None", per Nexqual as of June 10, 2026 at 00:54 UTC.
| Consensus Rating | None |
|---|
Earnings (HQH)
Source: Nexqual, June 10, 2026 at 00:54 UTC.
Financials & Fundamentals (HQH)
| Total Revenue | $5.54M |
|---|---|
| Revenue Growth (YoY) | -42.10% |
| Gross Margin | +100.00% |
| Operating Margin | -125.50% |
| Profit Margin | +4561.32% |
| ROE | +24.21% |
| Current Ratio | 1.03 |
| Total Debt | $0 |
Source: Nexqual, June 10, 2026 at 00:54 UTC.
Financial Health Score (HQH)
Nexqual rates HQH's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:54 UTC.
| Growth | Critical — Revenue -42% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Strong — ROE 24%, ROA -0.3% |
Ownership (HQH)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +22.98% |
| Shares Outstanding | 57.19M |
Source: Nexqual, June 10, 2026 at 00:54 UTC.
Leadership (HQH)
HQH is led by Jason C. Akus, Vice President of Research and Portfolio Manager, per Nexqual as of June 10, 2026 at 00:54 UTC.
| Vice President of Research and Portfolio Manager | Jason C. Akus |
|---|---|
| Senior Vice President of Research and Portfolio Manager | Christopher F. Brinzey |
| Senior Vice President of Research and Portfolio Manager | Frank T. Gentile (age 63) |
Major Backers & Investors (HQH)
Notable institutional backers of HQH include Morgan Stanley, Raymond James Financial, Inc., Penserra Capital Management LLC, according to Nexqual as of June 10, 2026 at 00:54 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 7.91% |
| Raymond James Financial, Inc. | 2.09% |
| Penserra Capital Management LLC | 2.01% |
| Amplify ETF Trust-Amplify CEF High Income ETF | 2% |
| Advisors Asset Management, Inc. | 1.01% |
| LPL Financial LLC | 0.97% |
| Royal Bank of Canada | 0.91% |
| Ameriprise Financial, Inc. | 0.82% |
Source: Nexqual, June 10, 2026 at 00:54 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HQL | TeklaLife Sciences Investors | USD 16.78 | ▼ 0.83% |
| THW | Tekla World Healthcare Fund Sha | USD 12.17 | ▼ 2.17% |
| THQ | Tekla Healthcare Opportunies Fu | USD 18.57 | ▲ 1.75% |
| RVT | Royce Value Trust, Inc. | USD 17.75 | ▲ 0.68% |
| UTF | Cohen & Steers Infrastructure F | USD 26.94 | ▼ 0.77% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:54 UTC. This page is informational and not investment advice.